

Message

---

**From:** Newhouse, Kathleen [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=5F019C8179304045ACD61BC05B571FB0-NEWHOUSE, KATHLEEN]  
**Sent:** 1/19/2017 10:11:19 PM  
**To:** Hogan, Karen [hogan.karen@epa.gov]  
**Subject:** FW: BAP Question

FYI

---

**From:** Newhouse, Kathleen  
**Sent:** Thursday, January 19, 2017 2:05 PM  
**To:** Olsen, Marian <Olsen.Marian@epa.gov>  
**Subject:** RE: BAP Question

Hi Marian

Ex. 5 Deliberative Process (DP)

## Ex. 5 Deliberative Process (DP)

Hopefully this is clear! Let me know if you have other questions.

-Kathleen

---

**From:** Olsen, Marian  
**Sent:** Thursday, January 19, 2017 1:56 PM  
**To:** Newhouse, Kathleen <Newhouse.Kathleen@epa.gov>  
**Subject:** BAP Question

Hi Kathleen,

A colleague in Region 2 asked whether the Relative Potency Factors for PAHs can be applied to the non-cancer Reference Dose for Benzo-a-pyrene. I was not able to locate a recommendation on this issue in the draft IRIS assessment. Kindly let me know if there is a specific recommendation for the application of Relative Potency Factors for PHAs.

Thanks for your help.

Marian